Kluft's Disease (Hypophosphatemic Rickets) – A Patient‑Focused Guide
Overview
Kluft’s disease, more formally known as X‑linked hypophosphatemic rickets (XLH)**, is a rare genetic disorder that impairs the kidney’s ability to reabsorb phosphate, leading to chronically low serum phosphate levels. Low phosphate interferes with normal bone mineralization, producing soft, weak bones that can bow, fracture, or cause pain.
Although the disease is named after Dr. T. Kluft, who described it in the 1940s, the modern term XLH reflects its most common inheritance pattern (X‑linked dominant). Autosomal‑dominant and recessive forms also exist but are far less frequent.
- Who it affects: Primarily males, because the gene is on the X chromosome, but females are also affected (often less severely). Symptoms usually appear in early childhood, often before age 2.
- Prevalence: Approximately 1 in 20,000 – 1 in 25,000 live births worldwide (CDC). The exact number may be higher due to under‑diagnosis.
Symptoms
Because low phosphate affects bone growth and mineralization, the symptom pattern evolves with age. Below is a comprehensive list:
Infancy & Early Childhood (0‑5 years)
- Delayed milestones: Crawling or walking later than peers.
- Bow‑leg deformities (genu varum) or knock‑knees (genu valgum): Visible curvature of the legs.
- Soft skull bones (craniotabes): Sensitive or soft spots on the head.
- Dental problems: Thin enamel, delayed tooth eruption, spontaneous cavities (dental abscesses).
- Bone pain or tenderness: Often described as “achey” legs after activity.
School‑Age & Adolescence (6‑18 years)
- Short stature: Height often 2‑3 SD below the mean for age.
- Growth plate (epiphyseal) abnormalities: Widened, irregular growth plates visible on X‑ray.
- Fractures: Low‑impact fractures, especially of the femur, tibia, or ribs.
- Muscle weakness: Difficulty climbing stairs or running.
- Hearing loss: Rare, due to ossicle abnormalities.
Adults (≥ 19 years)
- Persistent bone pain: Often in the lower back, hips, or chest.
- Osteomalacia: Softening of bones leading to fractures or pseudofractures (Looser zones).
- Enthesopathy: Calcification at tendon/ligament insertions causing stiffness.
- Nephrocalcinosis: Calcium deposition in kidneys, sometimes leading to reduced kidney function.
- Joint arthritis: Early‑onset degenerative changes, especially in the hips and knees.
- Dental complications: Recurrent abscesses, tooth loss.
Causes and Risk Factors
The disease is caused by mutations that affect the regulation of the hormone fibroblast growth factor‑23 (FGF‑23). Elevated FGF‑23 reduces renal phosphate reabsorption and suppresses vitamin D activation.
- Genetic cause: Over 300 mutations in the PHEX gene (X‑linked) account for > 80 % of cases. Autosomal‑dominant forms involve FGF23 or DMP1 mutations; recessive forms involve ENPP1 or TCIRG1.
- Inheritance: X‑linked dominant – a mother with the mutation has a 50 % chance of passing it to each child; affected males transmit the mutation to all daughters but none of their sons.
- Risk factors:
- Family history of rickets, short stature, or abnormal teeth.
- Consanguinity (more common in autosomal‑recessive forms).
- Being male (more severe phenotype).
Diagnosis
Timely diagnosis prevents irreversible bone deformities. Evaluation includes a combination of clinical, laboratory, and imaging studies.
Clinical assessment
- Detailed medical and family history.
- Physical exam focused on growth parameters, bone deformities, and dental health.
Laboratory tests
- Serum phosphate: Low (often < 2 mg/dL).
- Serum calcium: Usually normal.
- 25‑hydroxyvitamin D: Normal‑to‑low.
- 1,25‑dihydroxyvitamin D: Inappropriately low or normal despite low phosphate.
- Alkaline phosphatase (ALP):** Elevated, reflecting increased bone turnover.
- FGF‑23 level: Often markedly elevated (useful for confirming diagnosis).
- Renal function tests: Creatinine, BUN – to assess kidney involvement.
Imaging
- Plain radiographs: Show cupping, fraying, and metaphyseal widening at growth plates (“rickets” changes).
- Bone densitometry (DXA): Low bone mineral density.
- Kidney ultrasound: Detects nephrocalcinosis.
- Dental X‑rays: Identify enamel defects and pulp stones.
Genetic testing
Next‑generation sequencing panels for rickets‑related genes confirm the specific mutation. Testing is recommended for the patient and, when appropriate, for at‑risk family members.
Treatment Options
Management has evolved dramatically in the past decade. The goal is to normalize phosphate balance, promote bone mineralization, and prevent complications.
Conventional therapy
- Oral phosphate salts: Multiple doses daily (typically 30‑60 mg/kg/day divided 3–5 times). Requires careful monitoring for gastrointestinal upset and secondary hyperparathyroidism.
- Active vitamin D analogs: Calcitriol (0.05‑0.2 µg/kg/day) or alfacalcidol. These enhance intestinal calcium absorption and suppress secondary hyperparathyroidism.
- Both agents must be titrated using serum phosphate, calcium, ALP, and PTH levels.
Targeted therapy – Burosumab
Burosumab (brand name Crysvita®) is a fully human monoclonal antibody that binds and neutralizes FGF‑23, addressing the underlying pathophysiology.
- Dosage: Subcutaneous injection every 2 weeks (children) or every 4 weeks (adults), weight‑based.
- Efficacy: Clinical trials showed ↑ serum phosphate (+ 0.6‑1.0 mg/dL), ↓ ALP, improved growth velocity (+ 2‑4 cm/yr in children), and reduced bone pain (< 30 % of patients needed analgesics) (J Pediatr Endocrinol Metab, 2020).
- Safety: Most common adverse events are injection‑site reactions and transient hyperphosphatemia. Long‑term data (up to 5 years) show no increase in malignancy risk.
Surgical interventions
- Corrective osteotomies: For severe leg bowing not responsive to medical therapy.
- Dental extractions/ root canal: When recurrent abscesses occur.
Lifestyle & supportive measures
- Calcium‑rich diet (800‑1000 mg/day) – but avoid excess calcium supplements unless prescribed.
- Weight‑bearing activities (e.g., walking, swimming) to stimulate bone formation.
- Physical therapy for muscle strength and joint mobility.
- Regular dental hygiene and prompt treatment of cavities.
Living with Kluft's Disease (Hypophosphatemic Rickets)
Living with XLH is a lifelong partnership between the patient, family, and healthcare team.
Daily management tips
- Medication adherence: Take phosphate and vitamin D doses exactly as prescribed. Use a pill‑box or smartphone reminders.
- Monitor labs regularly: At least every 3‑6 months (more often during dose adjustments) for phosphate, calcium, PTH, and ALP.
- Stay hydrated: Adequate fluids lower the risk of kidney stones and nephrocalcinosis.
- Footwear: Supportive shoes or orthotics reduce stress on bowed limbs.
- School & work accommodations: Request extra breaks for medication dosing and consider ergonomic adjustments.
- Psychosocial support: Counseling or support groups (e.g., Rickets Foundation) can help cope with chronic disease stress.
Follow‑up schedule
- Endocrinology: Every 4‑6 months (more frequently in growing children).
- Nephrology: Annual ultrasound if on conventional therapy; sooner if kidney symptoms develop.
- Orthopedics: Yearly evaluation; sooner if new pain or deformity appears.
- Dentistry: Every 6 months; inform dentist of XLH diagnosis.
Prevention
Because XLH is genetic, primary prevention is not possible. However, secondary prevention focuses on early detection and minimizing complications.
- Family screening: Offer genetic testing to siblings and parents when a mutation is identified.
- Newborn assessment: In families with known XLH, measure serum phosphate within the first weeks of life.
- Vaccination: Maintain routine immunizations; some infections can exacerbate bone pain.
Complications
If left untreated or inadequately treated, hypophosphatemic rickets can lead to:
- Severe short stature – may be irreversible after epiphyses close.
- Permanent skeletal deformities requiring extensive surgery.
- Nephrocalcinosis or kidney stones – can progress to chronic kidney disease.
- Dental loss – recurrent infections may result in early tooth loss.
- Fractures and pseudofractures – increase morbidity and limit mobility.
- Secondary hyperparathyroidism – can cause bone resorption and hypercalcemia.
- Pain‑related disability – chronic pain may affect mental health.
When to Seek Emergency Care
- Sudden, severe bone pain that does not improve with usual analgesics.
- Acute swelling, redness, or warmth over a bone (possible fracture or infection).
- High fever (> 38.5 °C/101 °F) with chills and bone pain.
- Difficulty breathing or chest pain (could indicate a rib fracture or severe pulmonary complications from nephrocalcinosis).
- Sudden loss of vision, severe headache, or neurological changes (rare, but may signal intracranial calcifications).
- Signs of severe hypercalcemia: nausea, vomiting, confusion, irregular heartbeat.
Prompt evaluation can prevent permanent damage.
Key Takeaways
- Kluft’s disease (XLH) is a rare, inherited disorder that causes chronic low phosphate and weak bones.
- Early diagnosis (typically in infancy) and treatment—especially with the FGF‑23 antibody burosumab—dramatically improve growth, pain, and quality of life.
- Lifelong monitoring of labs, kidney health, and dental status is essential.
- Patients should stay vigilant for fractures, severe pain, or infection and seek emergency care when those arise.
For personalized advice, always discuss your symptoms and treatment options with a qualified endocrinologist or genetic specialist.
Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, Journal of Pediatric Endocrinology & Metabolism, New England Journal of Medicine (Burosumab trials).
```